Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments
Authors:
- Kristiina BoettigerKBKristiina Boettiger
- Ildikó KovácsIKIldikó Kovács
- Lilla HorvathLHLilla Horvath
- Büsra ErnhoferBEBüsra Ernhofer
- Karin SchelchKSKarin Schelch
- Maria Dorothea PozonecMPMaria Dorothea Pozonec
- Vivien TeglasVTVivien Teglas
- Clemens AignerCAClemens Aigner
- Evelyn MegyesfalviEMEvelyn Megyesfalvi
- Ferenc Rényi-VámosFRFerenc Rényi-Vámos
- Krisztina BogosKBKrisztina Bogos
- Christian LangCLChristian Lang
Open Access
- 18 December 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (5) , 1101-1112
Abstract
Small cell lung cancer (SCLC) is an aggressive thoracic disease characterized by rapid proliferation and early metastatic spread. The survival outcomes for patients with SCLC remain notoriously poor, underlining that only modest improvements have been achieved in clinical settings to date. However, insights gained from human tumors and preclinical models in recent years have shed light on the heterogeneous molecular profile of SCLC. Numerous research groups have, therefore, begun to stratify SCLC into subgroups based on differential transcription factor expression, the tumor immune microenvironment, and other criteria. As SCLC subtypes show major differences in their molecular landscape and biological behavior, they may offer unique therapeutic vulnerabilities and serve as a framework for future personalized clinical trials. Here, we summarize impactful classification attempts from the past 10 years, highlighting discrepancies and connections between the nomenclature of each study, and expound upon relevant factors of SCLC biology influencing subtype composition and plasticity. This review delves into the implications of subgrouping for understanding and treating SCLC, as well as potential future directions for SCLC research.Keywords
All Related Versions
Funding Information
- Austrian Science Fund (FWF I3522)
- Austrian Science Fund (FWF I3977)
- Austrian Science Fund (I4677)
- BIOSMALL (EU-HORIZON-MSCA-2022-SE-01)
- Hungarian National Research, Development, and Innovation Office (2020-1.1.6-JÖ)
- Hungarian National Research, Development, and Innovation Office (VŐ)
- Hungarian National Research, Development, and Innovation Office (TKP2021-EGA-33)
- Hungarian National Research, Development, and Innovation Office (FK-143751)
- Hungarian National Research, Development, and Innovation Office (FK-147045)
- New National Excellence Program of the Ministry for Innovation and Technology of Hungary (UNKP-20-3)
- New National Excellence Program of the Ministry for Innovation and Technology of Hungary (UNKP-21-3)
- New National Excellence Program of the Ministry for Innovation and Technology of Hungary (UNKP-23-5)
- Bolyai Research Scholarship of the Hungarian Academy of Sciences
- International Association for the Study of Lung Cancer/International Lung Cancer Foundation Young Investigator Grant
- Austrian Science Fund (T 1062-B33)
- Start-up Grant for Thoracic Oncological Projects Program of the Austrian Lung Cancer Group/Austrian Society of Pulmonology
This publication has 137 references indexed in Scilit:
- Candidate Biomarker of Response to Immunotherapy In Small Cell Lung CancerCurrent Treatment Options in Oncology, 2025
- Heterogeneity of molecular subtyping and therapy-related marker expression in primary tumors and paired lymph node metastases of small cell lung cancerVirchows Archiv, 2024
- Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)The Journal of Clinical Pharmacology, 2023
- In‐depth proteomic analysis reveals unique subtype‐specific signatures in human small‐cell lung cancerClinical and Translational Medicine, 2022
- Expression patterns and prognostic relevance of subtype‐specific transcription factors in surgically resected small‐cell lung cancer: an international multicenter studyThe Journal of Pathology, 2022
- Infiltrating T lymphocytes in the tumor microenvironment of small cell lung cancer: a state of knowledge reviewJournal of Cancer Research and Clinical Oncology, 2022
- Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4‐driven transcriptional stateMolecular Oncology, 2021
- Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distributionMolecular Oncology, 2020
- Exposure to secondhand tobacco smoke and lung cancer by histological type: A pooled analysis of the International Lung Cancer Consortium (ILCCO)International Journal of Cancer, 2014
- Surgical intervention for small-cell lung cancer: what is the surgical role?General Thoracic and Cardiovascular Surgery, 2012